Organigram Holdings Inc. (TSE:OGI – Free Report) – Equities researchers at Atb Cap Markets decreased their FY2025 EPS estimates for Organigram in a research report issued to clients and investors on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings per share of ($0.13) for the year, down from their prior estimate of ($0.12). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share.
OGI has been the subject of a number of other reports. ATB Capital reduced their price target on shares of Organigram from C$5.25 to C$3.50 in a research report on Tuesday. Canaccord Genuity Group reduced their target price on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research report on Monday, December 9th.
Organigram Stock Performance
Organigram stock opened at C$2.09 on Thursday. Organigram has a 1-year low of C$1.61 and a 1-year high of C$3.95. The company has a current ratio of 6.95, a quick ratio of 2.62 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of C$226.91 million, a PE ratio of -0.83, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The firm’s 50 day simple moving average is C$2.26 and its 200 day simple moving average is C$2.30.
Insiders Place Their Bets
In other Organigram news, Senior Officer Paolo De Luca sold 12,014 shares of the firm’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28. Corporate insiders own 31.32% of the company’s stock.
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Stories
- Five stocks we like better than Organigram
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Micron Stock Under $100: Seize the AI-Driven Upside
- What is a Special Dividend?
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- High Flyers: 3 Natural Gas Stocks for March 2022
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.